AptarGroup, Inc.

NYSE:ATR

Medical - Instruments & Supplies

Healthcare
$141.67 +0.55%

+$0.66 today

Market cap
$8.98B
Beta
0.40
P/E (TTM)
20.0
EPS (TTM)
$6.04
Dividend yield
1.57%
52W Low $103.23High $164.28

Volume 0.34M

Average 0.51M

ATR Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

AptarGroup, Inc.NYSE: ATR

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents rises 17.7% from a year ago

Cash & equivalents stood at $190.4M at the end of Q2 FY2026, up 17.7% from a year earlier and down 14.4% from the prior quarter. Over 3 fiscal years it compounded at +41.6% a year.

Context

  • Cash & equivalents amounted to 3.7% of total assets at the end of Q2 FY2026, up 0.4 pp from a year earlier.
  • Cash & equivalents increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +17.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$190.4M-14.4% QoQ
Last fiscal yearDec 2025
$402.42M+79.8% YoY
Year agoJun 2025
$161.73M+17.7% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.7%——
1 year+79.8%——
3-year CAGR+41.6%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
402.42M USD
Year-over-year change
+79.8%
4-year CAGR
+34.5%

Cash & Equivalents vs competitors

How ATR compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +17.7% is the 3rd highest of 7, against a peer median of -1.9%.
  • Cash & equivalents amounts to 3.7% of total assets for ATR, versus a peer median of 3.3%.
ATR Competitors
Cash & Equivalents for ATR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TRSTriMas CorporationMar 2026$1.31B USD+3903.7%-35.5%57.0%
AMCRAmcor plcJun 2026$1.12B USD+34.8%+17.4%3.0%
WSTWest Pharmaceutical Services, Inc.Jun 2026$435.8M USD-14.5%-4.0%10.7%
SLGNSilgan Holdings Inc.Jun 2026$351.5M USD+10.7%+22.7%3.7%
ATRAptarGroup, Inc.Jun 2026$190.4M USD+17.7%+41.6%3.7%
SONSonoco Products CompanySep 2026$183.1M USD-25.2%+18.5%1.8%
STVNStevanato Group S.p.A.Jun 2026€78.64M EUR-16.5%-17.1%3.0%
Peer median (excluding ATR) —-1.9%+6.7%3.3%

Competitors are the stored peer set for ATR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents122.93M141.73M223.64M223.84M402.42M
Short-term Investments740K002.34M7.11M
Net Receivables671.35M676.99M677.82M658.06M803.83M
Inventory441.46M486.81M513.05M461.81M537.85M
Other Current Assets0124.77M134.76M13.64M142.35M
Total Current Assets1.36B1.43B1.55B1.48B1.89B
Property, Plant & Equipment (Net)1.34B1.4B1.54B1.51B1.74B
Goodwill974.16M945.63M963.42M936.26M1.08B
Intangible Assets362.34M315.74M283.21M254.77M255.34M
Long-term Investments59.49M52.31M49.2M146.27M131.03M
Tax Assets00000
Other Non-current Assets48.84M57.14M69.64M105.24M152.71M
Total Non-current Assets2.78B2.77B2.9B2.95B3.36B
Total Assets4.14B4.2B4.45B4.43B5.25B
Account Payables285.26M320.28M328.57M295.97M340.56M
Short-term Debt285.88M122.79M458.22M338.29M343.53M
Tax Payables00000
Deferred Revenue86.95M80.24M60.51M64.43M74.83M
Other Current Liabilities195.31M206.33M222.01M211.44M232.6M
Total Current Liabilities982.49M917.18M1.25B1.07B1.17B
Long-term Debt907.02M1.05B681.19M688.07M1.14B
Deferred Tax Liabilities27.55M20.56M19.02M14.26M19.65M
Deferred Revenue (Non-current)21.91M25.36M37.76M00
Other Non-current Liabilities169.79M76.61M96.06M126.03M167.03M
Total Non-current Liabilities1.17B1.22B879.28M878.07M1.37B
Total Liabilities2.16B2.14B2.13B1.95B2.54B
Common Stock704K709K717K725K728K
Retained Earnings1.79B1.93B2.11B2.37B2.64B
Accumulated OCI(316.04M)(341.37M)(308.73M)(429.48M)(186.38M)
Other Stockholders Equity00000
Minority Interest15.19M14.27M14.47M14.04M44.13M
Total Equity1.98B2.07B2.32B2.49B2.71B
Total Debt1.24B1.22B1.18B1.08B1.53B
Net Debt1.12B1.08B961.03M852.22M1.13B

AptarGroup, Inc.

NYSE:ATR

Intrinsic Alpha fair value

Locked

Current Price

$141.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.